Thomas J. Dilworth - Concepedia

Author

Thomas J. Dilworth

University of New Mexico ORCID

Also Known As

Pooja Desai, Rebecca Schwartz, T Dilworth, Thomas Dilworth, Thomas J Dilworth, Thomas J. Dilworth

Publications

731

Citations

H-Index

Concepts

All Affiliations

University of New Mexico Aurora Health Care University of Wisconsin–Madison Wheaton Franciscan Healthcare University at Buffalo, State University of New York

About

Thomas J. Dilworth is an author at University of New Mexico specializing in medicine, antibiotics, and family medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	169
2	Education	1	1	55
3	Health Sciences	1	1	22
4	Nursing	1	1	55
5	Counseling	1	1	55

Thomas J. Dilworth

Publications

539

Citations

H-Index

Page 1

	Year	Citations
β-Lactams Enhance Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus Bacteremia Compared to Vancomycin Alone Thomas J. Dilworth, Omar M. Ibrahim, Pamela R. Hall, Antimicrobial Agents and Chemotherapy	2013	84
Impact of Pharmacist Discharge Medication Therapy Counseling and Disease State Education Preeyaporn Sarangarm, Matthew S. London, Stanley Snowden, American Journal of Medical Quality Family MedicineCounselingEducationPharmacotherapyDrug Treatment	2012	55
Early Administration of Adjuvant β‐Lactam Therapy in Combination with Vancomycin among Patients with Methicillin‐Resistant <i>Staphylococcus aureus</i> Bloodstream Infection: A Retrospective, Multicenter Analysis Anthony M. Casapao, David M. Jacobs, Dana R. Bowers, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2017	50
Evaluation of Vancomycin in Combination with Piperacillin-Tazobactam or Oxacillin against Clinical Methicillin-Resistant Staphylococcus aureus Isolates and Vancomycin-Intermediate S. aureus Isolates <i>In Vitro</i> Thomas J. Dilworth, Jora Sliwinski, Keenan Ryan, Antimicrobial Agents and Chemotherapy	2013	42
Vancomycin Advanced Therapeutic Drug Monitoring: Exercise in Futility or Virtuous Endeavor to Improve Drug Efficacy and Safety? Thomas J. Dilworth, Lucas Schulz, Warren E. Rose Clinical Infectious Diseases Vancomycin ExposureAntibiotic AdjuvantPharmacotherapyAntimicrobial ChemotherapyExcessive Vancomycin Tdm	2020	40
Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections Laura Clark, Lee P. Skrupky, R. Servais, Therapeutic Drug Monitoring	2019	37
Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study David M. Jacobs, Thomas J. Dilworth, Nicholas D. Beyda, Antimicrobial Agents and Chemotherapy	2017	35
Clinical and Economic Effects of a Pharmacist-Administered Antiretroviral Therapy Adherence Clinic for Patients Living with HIV Thomas J. Dilworth, Pamela W. Klein, Renée-Claude Mercier, Journal of Managed Care & Specialty Pharmacy	2018	33
Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant <i>Staphylococcus aureus</i> Endovascular Infections? Warren E. Rose, Cecilia Volk, Thomas J. Dilworth, Open Forum Infectious Diseases	2022	25
Vancomycin and Piperacillin-Tazobactam Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model Thomas J. Dilworth, Steve N. Leonard, A. Mary Vilay, Clinical Therapeutics AntibioticsVitro Pharmacokinetic/pharmacodynamic ModelPharmacologyVancomycin-intermediate Staphylococcus AureusAntibacterial Agent	2014	23

Page 1